	US 11,867,686 B2
	Method of selecting chemotherapeutic agents for an isolated organ or regional therapy
Eamonn P. Hobbs, Fort Lauderdale, FL (US); and Daniel S. Johnston, Martinsburg, WV (US)
Assigned to Delcath Systems, Inc., New York, NY (US)
Filed by Delcath Systems, Inc., New York, NY (US)
Filed on Jun. 4, 2020, as Appl. No. 16/893,358.
Application 16/893,358 is a continuation of application No. 15/346,239, filed on Nov. 8, 2016, abandoned.
Application 15/346,239 is a continuation of application No. 14/013,005, filed on Aug. 28, 2013, granted, now 9,541,544, issued on Jan. 10, 2017.
Claims priority of provisional application 61/694,143, filed on Aug. 28, 2012.
Prior Publication US 2020/0300839 A1, Sep. 24, 2020
This patent is subject to a terminal disclaimer.
Int. Cl. G01N 33/50 (2006.01)

CPC G01N 33/5011 (2013.01)

5 Claims

1. A method of obtaining and optimizing a chemotherapeutic agent filtration media pair for an isolated region or isolated organ treatment of a cancer in a mammal where blood is filtered to remove the chemotherapeutic agent before the blood is returned to the mammal, comprising:

screening a panel of chemotherapeutic agents with cancer cell lines for their capacity to induce cell death of the cancer cell lines to determine chemotherapeutic agents effective against the cancer;

identifying from the chemotherapeutic agents determined to be effective against the cancer a chemotherapeutic agent effective at treating the cancer at high dose and short term exposure of between 30 to 120 minutes by testing through a dose range of 0 to 20 times the maximal tolerated system concentration for the mammal to establish a dose in which at least 50% of cells of the cancer cell line do not survive;

determining a filtration media that comprises activated carbon to obtain a filtration media that can adsorb the chemotherapeutic agent from blood with an efficiency of at least 70% at flow rates of 100 to 1000 mL/minute,

by varying parameters of the activated carbon of a test media, wherein the parameters are selected from density, pore volume, surface area, pore size, and combinations thereof;

infusing a dose of the chemotherapeutic agent effective at treating the cancer at high dose and short term exposure in an extracorporeal circuit downstream of a blood source and upstream of a filter comprising the test media at a constant flow rate of from 100 to 1000 mL/minute, collecting blood samples at time intervals over a period of time of between 30 minutes and 120 minutes, and measuring the concentration of the chemotherapeutic agent effective against the cancer in the blood before the filter, pre filter concentration, and after the filter, post filter concentration, and calculating filtration efficiency,

wherein when a filter efficiency of at least 70% is obtained for the test media a chemotherapeutic agent filtration media pair has been obtained,

and optimizing the filtration media by varying parameters of the activated carbon of media of the chemotherapeutic agent filtration media pair, wherein the parameters are selected from density, pore volume, surface area, pore size, and combinations thereof;

infusing a dose of the chemotherapeutic agent effective at treating the cancer at high dose and short term exposure in an extracorporeal circuit downstream of a blood source and upstream of a filter comprising the activated carbon of media of the chemotherapeutic agent filtration media pair at a constant flow rate of from about 100 to about 1000 mL/minute, collecting blood samples at time intervals over a period of time of between 30 minutes and 120 minutes, and measuring the concentration of the chemotherapeutic agent effective against the cancer in the blood before the filter, pre filter concentration, and after the filter, post filter concentration, and calculating filtration efficiency, and wherein when a filter efficiency of at least 80% is obtained the filtration media of the chemotherapeutic agent filtration media pair has been optimized.